Clinical Trial Update: Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 2/Phase 3 study evaluating deutetrabenazine (Austedo) in Huntington disease, focusing on functional speech and gait; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• AUSTEDO (deutetrabenazine)

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Huntington Disease | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING